Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

Nature Medicine

Volumn 6, Issue 5, 2000, Pages 493-495

  Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME;

COLON TUMOR; HISTOCOMPATIBILITY; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T CELL LEUKEMIA; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY;

CELL DEATH; FAS LIGAND PROTEIN; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; MEMBRANE GLYCOPROTEINS; MODELS, IMMUNOLOGICAL; TRANSPLANTATION IMMUNOLOGY; TUMOR ESCAPE;

MUS MUSCULUS;

EID: 0034080750     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/74955     Document Type: Review

References (30)

1. O'Connell, J., Bennett, M.W., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. Fas counter-attack - the best form of tumor defense? Nature Med. 5, 267-268 (1999).
2. Vaux, D.L. Immunology. Ways around rejection. Nature 377, 576-577 (1995); retraction: 394,133 (1998).
3. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A. & Duke, R.C. A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632 (1995); erratum: 394, 133 (1998).
4. Lau, H.T., Yu, M., Fontana, A. & Stoeckert, C.J.J. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112 (1996).
5. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R. & Ferguson, T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
6. Yagita, H., Seino, K., Kayagaki, N. & Okumura, K. CD95 ligand in graft rejection. Nature 379, 682(1996).
7. Hahne, M., Rimoldi, D., Schroter, M., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366 (1996).
8. Allison, J., Georgiou, H.M., Strasser, A. & Vaux, D.L. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci USA 94, 3943-3947 (1997).
9. Kang, S.M. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3, 738-743 (1997).
10. Kang, S.M., Lin, Z., Ascher, N.L. & Stock, P.G. Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection. Transplant. Proc. 30, 538 (1998).
11. Kang, S.M., Hoffmann, A., Le, D., Springer, M.L., Stock, P.G. & Blau, H.M. Immune response and myoblasts that express Fas ligand. Science 278, 1322-1324 (1997).
12. Seino, K. et al. Attempts to reveal the mechanism of CD95-ligand-mediated inflammation. Transplant. Proc. 31, 1942-1943 (1999).
13. Seino, K. et al. Chemotactic activity of soluble Fas ligand against phagocytes. J.Immunol. 161, 4484-4488 (1998).
14. Seino, K., Kayagaki, N., Fukao, K., Okumura, K. & Yagita, H. Rejection of Fas ligand-expressing grafts. Transplant. Proc. 29, 1092-1093 (1997).
15. Seino, K., Kayagaki, N., Bashuda, H., Okumura, K. & Yagita, H. Contribution of Fas ligand to cardiac allograft rejection. Int. Immunol. 8, 1347-1354 (1996).
16. Chappell, D.B., Zaks, T.Z., Rosenberg, S.A. & Restifo, N.P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59, 59-62 (1999).
17. Arai, H., Gordon, D., Nabel, E.G. & Nabel, G.J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94, 13862-13867 (1997).
18. Hohlbaum, A.M., Moe, S. & Rothstein, A.M. Opposing Effects of Transmembrane and Soluble Fas Ligand Expression on Inflammation and Tumor Cell Survival. J. Exp. Med. 191, 1209-1220 (2000).
19. Muzio, M. et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - inducing signaling complex. Cell 85, 817-827 (1996).
20. Li, P. et al. Mice deficient in IL-1 β-converting enzyme are defective in production of mature IL-1 β and resistant to endotoxic shock. Cell 80, 401-411 (1995).
21. Ray, C.A. et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 β converting enzyme. Cell 69, 597-604 (1992).
22. Smith, D., Sieg, S. & Kaplan, D. Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J. Immunol. 160, 4159-4160 (1998).
23. Gastman, B.R. et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 59, 5356-5364 (1999).
24. De Maria, R. et al. Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation. J. Clin. Invest. 97, 316-322 (1996).
25. Fiedler, P., Schaetzlein, C.E. & Eibel, H. Constitutive expression of FasL in thyrocytes. Science 279, 2015a(1998).
26. Ekmekcioglu, S. et al. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res. 9, 261-272 (1999).
27. Henkart, P.A., Williams, M.S., Zacharchuk, C.M. & Sarin, A. Do CTL kill target cells by inducing apoptosis? Semin. Immunol. 9, 135-144 (1997).
28. Lenardo, M. et al. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17, 221-253 (1999).
29. Zaks, T.Z., Chappell, D.B., Rosenberg, S.A. & Restifo, N.P. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162, 3273-3279 (1999).
30. Chappell, D.B. & Restifo, N.P. T cell-tumor cell: a fatal interaction? Cancer Immunol. Immunother. 47, 65-71 (1998).